Royce & Associates LP Harvard Bioscience Inc Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

A detailed history of Royce & Associates LP transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Royce & Associates LP holds 1,451,450 shares of HBIO stock, worth $3.11 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,451,450
Previous 1,441,450 0.69%
Holding current value
$3.11 Million
Previous $4.11 Million 4.97%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024
BUY
$2.64 - $3.54 $26,400 - $35,400
10,000 Added 0.69%
1,451,450 $3.9 Million
Q2 2024

Aug 13, 2024
BUY
$2.77 - $4.63 $256,698 - $429,066
92,671 Added 6.87%
1,441,450 $4.11 Million
Q1 2024

May 13, 2024
SELL
$4.02 - $5.39 $410,240 - $550,049
-102,050 Reduced 7.03%
1,348,779 $5.72 Million
Q4 2023

Feb 12, 2024
BUY
$4.0 - $5.49 $160,800 - $220,698
40,200 Added 2.85%
1,450,829 $7.76 Million
Q3 2023

Nov 09, 2023
BUY
$4.0 - $5.82 $39,200 - $57,036
9,800 Added 0.7%
1,410,629 $6.07 Million
Q2 2023

Aug 07, 2023
SELL
$4.19 - $6.16 $160,699 - $236,254
-38,353 Reduced 2.66%
1,400,829 $7.69 Million
Q1 2023

May 04, 2023
BUY
$2.45 - $4.22 $35,081 - $60,426
14,319 Added 1.0%
1,439,182 $6.05 Million
Q4 2022

May 23, 2023
SELL
$2.12 - $2.86 $30,356 - $40,952
-14,319 Reduced 0.99%
1,424,863 $3.95 Million
Q4 2022

Feb 13, 2023
SELL
$2.12 - $2.86 $155,608 - $209,924
-73,400 Reduced 4.9%
1,424,863 $3.95 Million
Q3 2022

Nov 03, 2022
SELL
$2.33 - $3.92 $284,260 - $478,240
-122,000 Reduced 7.53%
1,498,263 $3.84 Million
Q2 2022

Aug 04, 2022
SELL
$3.28 - $6.42 $215,496 - $421,794
-65,700 Reduced 3.9%
1,620,263 $5.83 Million
Q1 2022

May 05, 2022
SELL
$5.16 - $7.14 $656,352 - $908,208
-127,200 Reduced 7.02%
1,685,963 $10.5 Million
Q4 2021

Feb 07, 2022
SELL
$6.37 - $8.18 $32,869 - $42,208
-5,160 Reduced 0.28%
1,813,163 $12.8 Million
Q3 2021

Nov 10, 2021
SELL
$6.98 - $8.47 $1.37 Million - $1.66 Million
-195,627 Reduced 9.71%
1,818,323 $12.7 Million
Q2 2021

Aug 06, 2021
BUY
$5.44 - $8.4 $522,240 - $806,400
96,000 Added 5.01%
2,013,950 $16.8 Million
Q1 2021

May 10, 2021
BUY
$3.91 - $6.99 $986,688 - $1.76 Million
252,350 Added 15.15%
1,917,950 $10.5 Million
Q4 2020

Feb 08, 2021
BUY
$3.0 - $4.5 $215,625 - $323,437
71,875 Added 4.51%
1,665,600 $7.15 Million
Q3 2020

Nov 12, 2020
SELL
$2.75 - $4.2 $772,406 - $1.18 Million
-280,875 Reduced 14.98%
1,593,725 $4.8 Million
Q2 2020

Aug 07, 2020
BUY
$2.12 - $3.14 $410,432 - $607,904
193,600 Added 11.52%
1,874,600 $5.81 Million
Q1 2020

May 12, 2020
BUY
$1.42 - $3.29 $42,600 - $98,700
30,000 Added 1.82%
1,681,000 $3.72 Million
Q4 2019

Feb 06, 2020
SELL
$2.45 - $3.25 $530,180 - $703,300
-216,400 Reduced 11.59%
1,651,000 $5.04 Million
Q3 2019

Nov 13, 2019
BUY
$1.59 - $3.47 $59,784 - $130,472
37,600 Added 2.05%
1,867,400 $5.74 Million
Q2 2019

Aug 12, 2019
BUY
$1.93 - $4.59 $192,228 - $457,164
99,600 Added 5.76%
1,829,800 $3.66 Million
Q4 2018

Feb 11, 2019
BUY
$3.03 - $5.0 $395,415 - $652,500
130,500 Added 8.16%
1,730,200 $5.5 Million
Q3 2018

Nov 13, 2018
BUY
$5.0 - $6.65 $173,500 - $230,755
34,700 Added 2.22%
1,599,700 $8.4 Million
Q2 2018

Aug 09, 2018
BUY
$4.2 - $5.95 $1.14 Million - $1.61 Million
270,306 Added 20.88%
1,565,000 $8.37 Million
Q1 2018

May 14, 2018
SELL
$3.3 - $5.15 $667,939 - $1.04 Million
-202,406 Reduced 13.52%
1,294,694 $6.47 Million
Q4 2017

Feb 09, 2018
SELL
$3.08 - $3.8 $186,340 - $229,900
-60,500 Reduced 3.88%
1,497,100 $4.94 Million
Q2 2017

Aug 07, 2017
BUY
N/A
1,557,600
1,557,600 $3.97 Million

Others Institutions Holding HBIO

# of Institutions
97
Shares Held
30.6M
Call Options Held
700
Put Options Held
2.1K
View Full List

About HARVARD BIOSCIENCE INC

HBIO Quotes by TradingView
  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $89.1M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email